Skip to main content

Update to Outpatient Drug Services Handbook for Belantamab Mafodontin-blmf (Blenrep)

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.

On July 1, 2023, the Texas Medicaid & Healthcare Partnership (TMHP) will update the Texas Medicaid Provider Procedures Manual, Outpatient Drug Services Handbook, section 6.8.2, “Belantamab Mafodontin-blmf (Blenrep),” to remove benefit information for procedure code J9037. The Food and Drug Administration (FDA) has withdrawn this injection drug.

For more information, call the TMHP Contact Center at 800-925-9126.